Lv4
428 积分 2025-01-10 加入
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis
1个月前
已完结
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
2个月前
已完结
Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA)
2个月前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2个月前
已完结
Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Non-alcoholic Steatohepatitis (NASH) and Stage 3 or Stage 4 Liver Fibrosis
4个月前
已关闭
Semaglutide 2.4 mg once weekly improved liver and metabolic parameters, and was well tolerated, in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
4个月前
已完结
A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
4个月前
已关闭
Relationship of Serum Chemerin Concentrations with Coronary Slow Flow: A Pathophysiological and Clinical Analysis
10个月前
已关闭
Uric Acid to Albumin Ratio in Coronary Slow Flow
10个月前
已完结
皖公网安备34019202002308
